CD99 and acute lymphoblastic leukemia: Additionally, anti-CD99 chimeric antigen receptor (CAR) T cells, expressing a low-affinity anti-CD99 antibody to avoid targeting normal blood cells, were explored as a potential therapeutic approach in ALL [44].